Numab is a Swiss biotech company that innovates and develops antibody-based therapeutics. A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane proteins. Numab’s proprietary discovery technology is particularly well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms.